Trial: 201811079

A Randomized Phase II Study of Atezolizumab (MPDL3280A) plus Recombinant Human IL-7 (CYT107) in patients with locally advanced or metastatic urothelial carcinoma

Phase

II

Principal Investigator

Pachynski, Russell

Disease Site

Urinary Bladder

Learn more about this study at: clinicaltrials.gov